Nobivac®

Lepto4 Vaccine

Protects against disease, mortality and urinary shedding. Featuring an even higher level of quality due to VacciPure filtration.

NOBIVAC LEPTO4 PROVIDES PROVEN PROTECTION AGAINST LEPTOSPIROSIS

The four-way leptospirosis vaccine is shown to be effective against disease, mortality and leptospiruria.

  • Aid in the prevention of disease and mortality caused by 4 virulent Leptospira serovars21
  • Protects against liver dysfunction and thrombocytopenia1
  • The only vaccine indicated to protect against mortality and leptospiruria
  • Prevents leptospiremia22
  • Proven safe and well tolerated in multiple studies1
  • Available in both a stand-alone and combination formulation (DAPPv)

INDICATIONS:

Shown to be effective against disease and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa.

Prevents leptospiruria associated with L. grippotyphosa, L. canicola, or L. icterohaemorrhagiae.

Aids in the prevention of leptospiruria associated with L. pomona.

Recommended for use in healthy dogs 8 weeks of age or older.

Unmatched Protection of Nobivac® Lepto4:Two Critical Indications

1. SHEDDING: DEFENSE AGAINST URINARY SHEDDING CAUSED BY 4 KEY LEPTOSPIRA SEROVARS

PREVENT URINARY SHEDDING OF LEPTOSPIRES22

A key objective of vaccination is to prevent urinary shedding of leptospires, which has potential zoonotic risk:22,23

  • 0% of dogs vaccinated with Nobivac® Canine 1-DAPPv+L4 developed leptospiruria
  • All of the control dogs challenged with L. canicola and L. grippotyphosa, 80% of control dogs challenged with L. icterohaemorrhagiae, and 50% of control dogs challenged with L. pomona developed leptospiruria

Nobivac® Lepto4 prevents leptospiruria associated with

  • L. grippotyphosa
  • L. canicola
  • L. icterohaemorrhagiae

Nobivac® Lepto4 shown to be effective against leptospiruria associated with

  • L. pomona

2. MORTALITY: THE ONLY LEPTOSPIROSIS VACCINE INDICATED TO AID IN THE PREVENTION OF DISEASE AND MORTALITY

PROTECTION FOR DOGS FACING THE MOST SEVERE CHALLENGES21

  • No dogs vaccinated with Nobivac® Canine 1-DAPPv+L4 died or required euthanasia
  • 54% mortality and euthanasia in control groups, reflecting the severity of challenge

Clinical efficacy results showed that Nobivac® Canine 1-DAPPv+L4 also prevented1

  • Leptospiremia
    • 100% vaccinates had no leptospiremia; leptospires were cleared quickly from the blood in those that did
    • By contrast, all control dogs had leptospiremia, and it lasted significantly longer, by days
  • Liver dysfunction
    • Serum levels of bilirubin and AST* remained at normal levels in significantly more vaccinates
  • Thrombocytopenia
    • Platelet counts remained in the normal range

* AST = aspartate aminotransferase

UNMATCHED PROTECTION

NOBIVAC LEPTO4 IS THE CLEAR CHOICE WHEN COMPARED WITH OTHER 4-WAY LEPTOSPIROSIS VACCINES24-27

 

No items to show.

Loading…

VacciPureFiltration Technology

REDUCED TOTAL PROTEINS THROUGH VACCIPURE

Fewer total proteins (TP) means a more purified final product, which may reduce unwanted immune system responses, such as vaccine reactions.1

 

THE ADVANCED VACCIPURE™ FILTRATION TECHNOLOGY

watch

FILTRATION PROCESS LEADS TO IMPROVED VACCINES1

To promote an even higher level of vaccine quality, Merck Animal Health introduced the special VacciPure filtration process in manufacturing Nobivac® Lepto4 and Nobivac® Canine 1-DAPPV+L4

A porous filtration membrane selectively removes extraneous proteins, salts, and solvents

  • The outcome – fewer total proteins and a more purified final product
watch

No items to show.

Loading…

NOBIVAC® LEPTO4 IS A SAFE CHOICE

  • Safety confirmed in a 749-dog field study1
  • Well tolerated on subcutenous administration
  • Proven safe across a variety of breeds and ages
  • Now featuring an even higher level of quality due to the VacciPure filtration

ADMINISTRATION AND DOSAGE

  • Subcutaneous injection
  • Two 1 mL doses given 2-4 weeks apart
  • Annual revaccination with one dose is recommended
  • Available in a 25 x 1 mL dose presentation

DISEASE INFORMATION

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

Quick Guide to Lepto

eBook

A handy guide to protect dogs and prevent the spread of leptospirosis.

Download

Standard Operating Procedure

Video

Learn why it’s important to have a Standard Operating Procedure to reduce the risk of leptospirosis in your practice.

watch

No items to show.

Loading…

References:

1. Data on file, Merck Animal Health. 

21. LaFleur RL, Dant JC, Wasmoen TL. Prevention of disease and mortality in vaccinated dogs following experimental challenge with virulent leptospira. J Vet Int Med, May/June 2011, Vol 25, Issue 3; 747. 

22. LaFleur RL, Dant JC, Tubbs AL, et al. Prevention of leptospiremia and leptospiruria following vaccination with a DAPPv + 4-way leptospira combination vaccine. Abstract & Poster, ISCAID meeting, Bristol, UK, 2016. 

23. J.E. Sykes, K. Hartmann, K.F. Lunn, et al. 2010 ACVIM Small Animal Consensus Statement on Leptospirosis: Diagnosis, Epidemiology, Treatment, and Prevention. J Vet Intern Med 2011; 25: 1–13. 

24. Nobivac® Lepto4 [product label], Madison, NJ: Merck Animal Health; 2018. 

25. VANGUARD® L4 [product label]. Florham Park, NJ: Zoetis, Inc; 2018. 

26. RECOMBITEK® 4 Lepto [product label]. Duluth, GA: Boehringer Ingelheim Animal Health; 2018. 

27. ULTRA™ Duramune® 4L, LEPTOVAX® 4 [product labels]. Greenfield, IN: Elanco; 2018.

View All Nobivac References